Patents by Inventor Ulrich Klar

Ulrich Klar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10981932
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical 2019 compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 20, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Clara Christ, Kai Thede, Joachim Kuhnke, Manfred Moewes, Knut Eis, Amaury Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Philip Lienau, Ulrike Sack, Arne Scholz, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren
  • Publication number: 20210085656
    Abstract: The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 3, 2020
    Publication date: March 25, 2021
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ulrich KLAR, Rolf BOHLMANN, Heike SCHÄCKE, Detlev SÜLZLE, Stephan MENZ, Olaf PANKNIN
  • Publication number: 20210079018
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 15, 2018
    Publication date: March 18, 2021
    Inventors: Steven J. Ferrara, Michael H. Serrano-Wu, Christopher Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Laura Furst, Guo Wei, Patrick Ryan MacCarren, Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Sack, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Mönning
  • Publication number: 20200216439
    Abstract: Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: December 12, 2016
    Publication date: July 9, 2020
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Gerhard SIEMEISTER, Ursula MÖNNING, Franz VON NUSSBAUM
  • Publication number: 20200087322
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: May 17, 2017
    Publication date: March 19, 2020
    Inventors: Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Clara Christ, Kai Thede, Joachim Kuhnke, Manfred Moewes, Knut Eis, Amaury Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Philip Lienau, Ulrike Sack, Arne Scholz, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren
  • Publication number: 20190388425
    Abstract: The present invention relates to substituted imidazopyridinpyrimidine compounds of general formula (I) which inhibit MKNK1 and MKNK2 kinase (also known as MAP Kinase interacting Kinase, Mnk1 and Mnk2), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: January 19, 2018
    Publication date: December 26, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ulrich KLAR, Heike SCHÄCKE, Detlev SÜLZLE, Stephan MENZ
  • Patent number: 10487092
    Abstract: The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: November 26, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Anja Giese, Ulrich Klar, Keith Graham, Georg Kettschau, Detlev Sülzle, Philip Lienau, Kirstin Petersen, Julien LeFranc, Nicole Schmidt
  • Publication number: 20190350910
    Abstract: The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (A) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: January 15, 2018
    Publication date: November 21, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ulrich KLAR, Rolf BOHLMANN, Heike SCHÄCKE, Detlev SÜLZLE, Stephan MENZ, Olaf PANKNIN
  • Patent number: 10428044
    Abstract: Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: October 1, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Keith Graham, Ulrich Klar, Hans Briem, Marion Hitchcock, Lars Bärfacker, Knut Eis, Volker Schulze, Gerhard Siemeister, Wilhelm Bone, Jens Schröder, Simon Holton, Philip Lienau, René Tempel, Helmut Sonnenschein, Jozsef Bálint, Heinz Graubaum
  • Patent number: 10428063
    Abstract: Compound of formula (I), processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: October 1, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Keith Graham, Ulrich Klar, Hans Briem, Volker Schulze, Gerhard Siemeister, Philip Lienau, René Tempel, Jozsef Bálint
  • Patent number: 10308629
    Abstract: Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: June 4, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith Graham, Ulrich Klar, Hans Briem, Gerhard Siemeister, Ursula Mönning
  • Patent number: 10227299
    Abstract: Compounds of formula (I) as described herein processes for their production and their use as anti-cancer agents.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: March 12, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith Graham, Ulrich Klar, Hans Briem, Gerhard Siemeister, Ursula Mönning, Jozsef Balint
  • Patent number: 10155004
    Abstract: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: December 18, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Wolfgang Schwede, Ulrich Klar, Carsten Moller, Andrea Rotgeri, Wilhelm Bone
  • Publication number: 20180222881
    Abstract: Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: August 1, 2016
    Publication date: August 9, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Gerhard SIEMEISTER, Ursula M?NNING
  • Publication number: 20180162877
    Abstract: The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 14, 2018
    Inventors: Anja GIESE, Ulrich KLAR, Keith GRAHAM, Georg KETTSCHAU, Detlev SÜLZLE, Philip LIENAU, Kirstin PETERSEN, Julien LEFRANC, Nicole SCHMIDT
  • Publication number: 20180155285
    Abstract: Compounds of formula (I) as described hereinprocesses for their production and their use as anti-cancer agents.
    Type: Application
    Filed: June 14, 2016
    Publication date: June 7, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Gerhard SIEMEISTER, Ursula MÕNNING, Jozsef BALINT
  • Publication number: 20180016272
    Abstract: Compound of formula (I), processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: January 25, 2016
    Publication date: January 18, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Volker SCHULZE, Gerhard SIEMEISTER, Philip LIENAU, René TEMPEL, Jozsef BÁLINT
  • Patent number: 9717739
    Abstract: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 1, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Wolfgang Schwede, Ulrich Klar, Carsten Moller, Andrea Rotgeri, Wilhelm Bone
  • Publication number: 20170202857
    Abstract: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.
    Type: Application
    Filed: April 4, 2017
    Publication date: July 20, 2017
    Inventors: Wolfgang SCHWEDE, Ulrich KLAR, Carsten MOLLER, Andrea ROTGERI, Wilhelm BONE
  • Publication number: 20170197979
    Abstract: The present invention relates to substituted benzothiadiazolamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: May 26, 2015
    Publication date: July 13, 2017
    Inventors: Anja GIESE, Ulrich KLAR, Georg KETTSCHAU, Detlev SÜLZLE, Philip LIENAU, Kirstin PETERSEN